12 terminated. 12 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Terminated 12 |
| Phase 1 | 3 | Terminated 3 |
| Phase 3 | 2 | Terminated 2 |
Follow Primary Dysautonomias: new trials by email Literature Review of Primary Dysautonomias trials Research Report on Primary Dysautonomias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA) KM-819, Placebo - Multiple System Atrophy | Phase 2 | Terminated | Kainos Medicine Inc. | 68 | 2023-02-27 | 2024-09-19 |
| A Futility Trial of Sirolimus in Multiple System Atrophy Sirolimus 2 MG, Placebo - Multiple System Atrophy | Phase 2 | Terminated | NYU Langone Health | 47 | 2018-09-01 | 2021-12-07 |
| Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS) Northera (Droxidopa), Placebo - Postural Tachycardia Syndrome (POTS), Vasovagal Syncope (VVS) | Phase 2 | Terminated | New York Medical College | 30 | 2015-09-01 | 2025-05-23 |
| Iron Sucrose in Adolescents With Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS) Iron infusion, Normal saline infusion - Postural Orthostatic Tachycardia Syndrome | Phase 1 / Phase 2 | Terminated | Mayo Clinic | 3 | 2014-12-17 | 2017-11-17 |
| Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist Droxidopa, Atenolol, Placebos - Postural Orthostatic Tachycardia Syndrome, Orthostatic Intolerance | Phase 1 / Phase 2 | Terminated | Beth Israel Deaconess Medical Center | 8 | 2011-08-15 | 2017-05-18 |
| Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome Droxidopa - Chronic Fatigue Syndrome, Orthostatic Hypotension | Phase 2 | Terminated | Chelsea Therapeutics | 3 | 2010-07-01 | 2014-06-09 |
| Lithium in Multiple System Atrophy Lithium Carbonate, Placebo - Multiple System Atrophy | Phase 2 | Terminated | Federico II University | 10 | 2009-10-01 | 2014-02-03 |
| Mechanisms of Hypoglycemia Associated Autonomic Failure naloxone, fructose, exercise - Diabetes Mellitus, Hypoglycemia | Phase 2 | Terminated | Albert Einstein College of Medicine | 39 | 2008-03-01 | 2026-05-19 |
| Augmenting Effects of L-DOPS With Carbidopa and Entacapone Droxidopa, Carbidopa, Entacapone - Parkinson Disease, Multiple System Atrophy | Phase 1 / Phase 2 | Terminated | National Institute of Neurological Disorders and Stroke (NINDS) | 14 | 2007-10-01 | 2014-07-17 |
| Effects of Pulsatile Intravenous Insulin Therapy on Metabolic Integrity in Patients With Diabetes Mellitus Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog) - Diabetes Mellitus, With Complications | Phase 2 / Phase 3 | Terminated | Florida Atlantic University | 152 | 2006-11-01 | 2016-08-10 |
| Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS) 3-4 Diaminopyridine - Muscle Weakness | Phase 2 | Terminated | Jeffrey A. Cohen, MD | 4 | 2004-02-01 | 2019-05-21 |
| Treatment of Orthostatic Hypotension Droxidopa Oral Product - Autonomic Nervous System Diseases, Orthostatic Hypotension | Phase 2 / Phase 3 | Terminated | Vanderbilt University | 8 | 2004-01-01 | 2022-03-02 |
Multiple System Atrophy (4) · Hypotension, Orthostatic (3) · Orthostatic Intolerance (3) · Postural Orthostatic Tachycardia Syndrome (3) · Autonomic Nervous System Diseases (2) · Diabetes Mellitus (2) · Diabetes Complications (1) · Diabetes Mellitus, Type 1 (1) · Dizziness (1) · Fatigue Syndrome, Chronic (1) · Hypoglycemia (1) · Muscle Weakness (1) · Neurodegenerative Diseases (1) · Parkinson Disease (1)
Nervous System Diseases (12) · Autonomic Nervous System Diseases (10) · Pathological Conditions, Signs and Symptoms (5) · Basal Ganglia Diseases (4) · Brain Diseases (4) · Cardiovascular Diseases (4) · Central Nervous System Diseases (4) · Movement Disorders (4) · Neurologic Manifestations (4) · Signs and Symptoms (4) · Synucleinopathies (4) · Hypotension (3) · Neurodegenerative Diseases (3) · Orthostatic Intolerance (3)
Droxidopa (5) · Insulin (2) · 3,4-dihydroxyphenylserine aldolase (1) · Atenolol (1) · Carbidopa (1) · Epinephrine (1) · Exercise (1) · Ferric Oxide, Saccharated (1) · Fructose (1) · Insulin Aspart (1) · KM-819 (1) · Lithium Carbonate (1) · Morphine (1) · Naloxone (1) · Saline Solution (1)
Albert Einstein College of Medicine (1) · Beth Israel Deaconess Medical Center (1) · Chelsea Therapeutics (1) · Federico II University (1) · Florida Atlantic University (1) · Jeffrey A. Cohen, MD (1) · Kainos Medicine Inc. (1) · Mayo Clinic (1) · NYU Langone Health (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · New York Medical College (1) · Vanderbilt University (1)
United States (10) · Italy (1) · South Korea (1)
Alessandro Filla, MD (1) · Amie Jones, MD (1) · Betty Tuller, PhD (1) · Charles W Lapp, M.D. (1) · Chong Sik Lee (1) · David Robertson, MD (1) · David S Goldstein, M.D. (1) · Jeffrey A. Cohen, MD (1) · Jose-Alberto Palma, MD, PhD (1) · Julian M Stewart, M.D., Ph.D. (1) · Meredith Hawkins, M.D., M.S. (1) · Roy Freeman, MD (1)
PMID 22522612, PMID 28860128, PMID 35040506
P01HL056693 (1), R01DK079974 (1), R01HL059459 (1)